Outcomes of de novo belatacept‐based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization
暂无分享,去创建一个
D. Serur | Vikram Wadhera | Y. Yushkov | Tara Shertel | Ankita Patel | M. Wynd | Benjamin Schleich | Michael Goldstein